Autotaxin and lysophospholipids in rheumatoid arthritis

Current Opinion in Investigational Drugs

Volumn 11, Issue 5, 2010, Pages 515-526

  Bourgoin, Sylvain G ^a,b   Zhao, Chenqi ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Autotaxin; Cancer; Lysophosphatidic acid; Metastasis; Rheumatoid arthritis; Sphingosine 1 phosphate

Indexed keywords

1 OLEOYL 2 O METHYLRACGLYCEROPHOSPHOTHIONATE; 4 (2,6 DICHLORO 4 PYRIDINYL) 1 (1,3 DIMETHYL 4 ISOPROPYL 1H PYRAZOLO[3,4 B]PYRIDIN 6 YL)SEMICARBAZIDE; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; ALPHA BROMOMETHYLENE PHOSPHONATE; ANTIRHEUMATIC AGENT; AUTOTAXIN; BITHIONOL; CAY 10444; CELL SURFACE RECEPTOR; CHEMOKINE; CYTOKINE; DEBIO 0719; DIACYLGLYCEROL PYROPHOSPHATE; FINGOLIMOD; H 2 L 795958; KI 16425; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID; NSC 48300; PYROPHOSPHATE; S 32826; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; VPC 32183; VPC 8 A 202;

ADJUVANT ARTHRITIS; CELL FUNCTION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE RELEASE; DRUG MECHANISM; DRUG TARGETING; FIBROBLAST; HELMINTHIASIS; HUMAN; IC 50; INFLAMMATION; MEDIATOR RELEASE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE;

EID: 77952141210     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, Liotta LA: Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem (1992) 267(4):2524-2529.
2. Clair T, Aoki J, Koh E, Bandle RW, Nam SW, Ptaszynska MM, Mills GB, Schiffmann E, Liotta LA, Stracke ML: Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res (2003) 63(17):5446-5453.
3. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K: Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem (2002) 277(42):39436-39442.
4. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 158(2):227-233. •• Describes ATX, a member of the nucleotide pyrophosphatase/PDE family of ecto-enzymes that is identical to plasma lysoPLD and acts by hydrolyzing LPC to LPA, a lipid mediator that promotes cell proliferation, migration and cell survival. The production of LPA by ATX accounts for the biological effect of ATX on various cancer cell lines in vitro.
5. Pyne S, Lee SC, Long J, Pyne NJ: Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal (2009) 21(1):14-21.
6. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH: The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J (1993) 291 (Pt 3) : 677-680.
7. Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi R, Asazuma N, Satoh K, Ozaki Y, Kume S: Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem (1997) 121(5):969-973.
8. Makide K, Kitamura H, Sato Y, Okutani M, Aoki J: Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins Other Lipid Mediat (2009) 89 (3-4) : 135-139.
9. Feldmann M, Brennan FM, Maini RN: Rheumatoid arthritis. Cell (1996) 85(3):307-310.
10. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol (1996) 14:397-440.
11. McInnes IB, Schett G: Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol (2007) 7(6):429-442.
12. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW: Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet (1988) 2(8613):706-709.
13. Saxne T, Palladino MA Jr, Heinegård D, Talal N, Wollheim FA: Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fuid and serum. Arthritis Rheum (1988) 31(8):1041-1045.
14. Müller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, Gay S: Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol (1996) 149(5):1607-1615.
15. 3 receptor and enhance inflammatory cytokines/chemokines in response to LPA, an effect that may exacerbate the disease process.
16. Nochi H, Tomura H, Tobo M, Tanaka N, Sato K, Shinozaki T, Kobayashi T, Takagishi K, Ohta H, Okajima F, Tamoto K: Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fuid of patients with rheumatoid arthritis in fibroblast-like synovial cells. J Immunol (2008) 181(7):5111-5119. • Describes the monitoring of LPA levels in synovial fuids from patients with RA and OA.
17. 2.
18. 3 receptor and enhanced the secretion of inflammatory cytokines/chemokines in response to S1P. This study demonstrated that S1P protects synoviocytes firom apoptosis.
19. Kawagoe H, Stracke ML, Nakamura H, Sano K: Expression and transcriptional regulation of the PD-Iα/autotaxin gene in neuroblastoma. Cancer Res (1997) 57(12):2516-2521. (Pubitemid 27255915)
20. Yang SY, Lee J, Park CG, Kim S, Hong S, Chung HC, Min SK, Han JW, Lee HW, Lee HY: Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis (2002) 19(7):603-608.
21. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, Yamori T, Aoki J, Fujimaki T, Arai H: Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem (2006) 281(25):17492-17500.
22. Euer N, Schwirzke M, Evtimova V, Burtscher H, Jarsch M, Tarin D, Weidle UH: Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. Anticancer Res (2002) 22 (2A) : 733-740.
23. Liliom K, Sun G, Bünemann M, Virág T, Nusser N, Baker DL, Wang DA, Fabian MJ, Brandts B, Bender K, Eickel A et al: Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: A possible role in regulating cardiac function via sphingolipid receptors. Biochem J (2001) 355 (Pt 1) : 189-197.
24. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem (2006) 281(35):25822-25830.
25. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH et al: Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol (2006) 26(13):5015-5022. •• Decribes a gene-targeting study that determined an essential role for ATX in stabilizing blood vessels during embryonic development. ATX was demonstrated to be the major source of plasma LPA, but not S1P, levels in vivo.
26. An S, Bleu T, Hallmark OG, Goetzl EJ: Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem (1998) 273(14):7906-7910. (Pubitemid 28168837)
27. Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, Tsujimoto M, Arai H, Inoue K: Molecular cloning and characterization of a novel human G-proteincoupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem (1999) 274(39):27776-27785.
28. Hecht JH, Weiner JA, Post SR, Chun J: Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol (1996) 135(4):1071-1083.
29. Noguchi K, Ishii S, Shimizu T: Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem (2003) 278(28):25600-25606.
30. 5. J Biol Chem (2006) 281(33):23589-23597.
31. 5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet (2008) 40(3):329-334.
32. 5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair. Nat Genet (2008) 40(3):335-339.
33. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N: The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun (2007) 363(3):861-866.
34. 10 receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun (2008) 371(4):707-712.
35. Hooks SB, Santos WL, Im DS, Heise CE, Macdonald TL, Lynch KR: Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J Biol Chem (2001) 276(7):4611-4621.
36. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC, Zimmerman GA, Hama K, Aoki J, Arai H, Prestwich GD: Identification of an intracellular receptor for lysophosphatidic acid (LPA) : LPA is a transcellular PPARγ agonist. Proc Natl Acad Sci USA (2003) 100(1):131-136. (Pubitemid 36078041)
37. Moolenaar WH, van Meeteren LA, Giepmans BN: The ins and outs of lysophosphatidic acid signaling. Bioessays (2004) 26(8):870-881.
38. Pietruck F, Busch S, Virchow S, Brockmeyer N, Siffert W: Signalling properties of lysophosphatidic acid in primary human skin fibroblasts: Role of pertussis toxin-sensitive GTP-binding proteins. Naunyn Schmiedebergs Arch Pharmacol (1997) 355(1):1-7.
39. Thoreson WB, Ryan JS, Shi C, Kelly ME, Bryson EJ, Toews ML, Ediger TL, Chacko DM: Lysophosphatidic acid receptor signaling in mammalian retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (2002) 43(7):2450-2461.
40. 1/edg2- receptor: Involvement of a nonclassical pathway? Mol Endocrinol (2003) 17(8):1593-1606.
41. Stahle M, Veit C, Bachfscher U, Schierling K, Skripczynski B, Hall A, Gierschik P, Giehl K: Mechanisms in LPA-induced tumor cell migration: Critical role of phosphorylated ERK. J Cell Sci (2003) 116 (Pt 18) : 3835-3846.
42. Peres C, Yart A, Perret B, Salles JP, Raynal P: Modulation of phosphoinositide 3-kinase activation by cholesterol level suggests a novel positive role for lipid rafts in lysophosphatidic acid signalling. FEBS Lett (2003) 534 (1-3) : 164-168.
43. Yart A, Chap H, Raynal P: Phosphoinositide 3-kinases in lysophosphatidic acid signaling: Regulation and cross-talk with the Ras/mitogen-activated protein kinase pathway. Biochim Biophys Acta (2002) 1582 (1-3) : 107-111.
44. i in skeletal muscle cells. J Cell Mol Med (2008) 12(3):942-954.
45. Hahn A, Barth H, Kress M, Mertens PR, Goppelt-Struebe M: Role of Rac and Cdc42 in lysophosphatidic acid-mediated cyclo-oxygenase-2 gene expression. Biochem J (2002) 362 (Pt 1) : 33-40.
46. Anliker B, Chun J: Lysophospholipid G protein-coupled receptors. J Biol Chem (2004) 279(20):20555-20558.
47. Ishii I, Fukushima N, Ye X, Chun J: Lysophospholipid receptors: Signaling and biology. Annu Rev Biochem (2004) 73:321-354.
48. Sanchez T, Hla T: Structural and functional characteristics of S1P receptors. J Cell Biochem (2004) 92(5):913-922.
49. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D: Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest (2001) 108(5):689-701.
50. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'af RI, Hla T: Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell (1999) 99(3):301-312.
51. Lee MJ, Thangada S, Paik JH, Sapkota GP, Ancellin N, Chae SS, Wu M, Morales-Ruiz M, Sessa WC, Alessi DR, Hla T: Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol Cell (2001) 8(3):693-704.
52. Ancellin N, Hla T: Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5. J Biol Chem (1999) 274(27):18997-19002.
53. i pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol (2003) 23(5):1534-1545.
54. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S: Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem (2009) 78:743-768.
55. Choi JW, Lee CW, Chun J: Biological roles of lysophospholipid receptors revealed by genetic null mice: An update. Biochim Biophys Acta (2008) 1781(9):531-539.
56. Santos AN, Riemann D, Santos AN, Kehlen A, Thiele K, Langner J: Treatment of fibroblast-like synoviocytes with IFN-γ results in the down-regulation of autotaxin mRNA. Biochem Biophys Res Commun (1996) 229(2):419-424.
57. Kehlen A, Lauterbach R, Santos AN, Thiele K, Kabisch U, Weber E, Riemann D, Langner J: IL-1 β-and IL-4-induced downregulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin Exp Immunol (2001) 123(1):147-154.
58. 2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell (1995) 80(6):919-927.
59. 2 induces vascular endothelial cell migration. Blood (2000) 96(12):3809-3815.
60. Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, Mizuno K, Saku K, Taguchi R, Arai H: Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem (2002) 277(50):48737-48744.
61. Lai WQ, Irwan AW, Goh HH, Howe HS, Yu DT, Valle-Onate R, McInnes IB, Melendez AJ, Leung BP: Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis. J Immunol (2008) 181(11):8010-8017.
62. Stortelers C, Kerkhoven R, Moolenaar WH: Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling. BMC Genomics (2008) 9:387.
63. Shiozawa S, Shiozawa K, Fujita T: Morphologic observations in the early phase of the cartilage-pannus junction. Light and electron microscopic studies of active cellular pannus. Arthritis Rheum (1983) 26(4):472-478.
64. Koch AE: Chemokines and their receptors in rheumatoid arthritis: Future targets? Arthritis Rheum (2005) 52(3):710-721.
65. 2 production by lung fibroblasts. Am J Respir Cell Mol Biol (2004) 30(1):91-100.
66. Blanco-Rivero J, Cachofeiro V, Lahera V, Aras-Lopez R, Márquez-Rodas I, Salaices M, Xavier FE, Ferrer M, Balfagón G: Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension (2005) 46(1):107-112.
67. Dempke W, Rie C, Grothey A, Schmoll HJ: Cyclooxygenase-2: A novel target for cancer chemotherapy? J Cancer Res Clin Oncol (2001) 127(7):411-417.
68. Krysan K, Reckamp KL, Sharma S, Dubinett SM: The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem (2006) 6(3):209-220.
69. 2 synthesis enzymes and its temporal relation to fever. Neurosci Res (2002) 44(1):51-61.
70. Hidaka T, Suzuki K, Kawakami M, Okada M, Kataharada K, Shinohara T, Takamizawa-Matsumoto M, Ohsuzu F: Dynamic changes in cytokine levels in serum and synovial fuid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apher (2001) 16(2):74-81.
71. Lettesjo H, Nordström E, Strom H, Nilsson B, Glinghammar B, Dahlstedt L, Möller E: Synovial fuid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand J Immunol (1998) 48(3):286-292. (Pubitemid 28416972)
72. Martel-Pelletier J, Pelletier J P, Fahmi H: Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum (2003) 33(3):155-167.
73. Ospelt C, Neidhart M, Gay RE, Gay S: Synovial activation in rheumatoid arthritis. Front Biosci (2004) 9:2323-2334.
74. Pi X, Tan SY, Hayes M, Xiao L, Shayman JA, Ling S, Holoshitz J: Sphingosine kinase 1-mediated inhibition of Fas death signaling in rheumatoid arthritis B lymphoblastoid cells. Arthritis Rheum (2006) 54(3):754-764.
75. Knedla A, Neumann E, Müller-Ladner U: Developments in the synovial biology feld 2006. Arthritis Res Ther (2007) 9(2):209.
76. Firestein GS: Evolving concepts of rheumatoid arthritis. Nature (2003) 423(6937):356-361.
77. Baker MS, Green SP, Lowther DA: Changes in the viscosity of hyaluronic acid after exposure to a myeloperoxidase-derived oxidant. Arthritis Rheum (1989) 32(4):461-467.
78. Tak PP, Bresnihan B: The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. Arthritis Rheum (2000) 43(12):2619-2633.
79. Cross A, Bakstad D, Allen JC, Thomas L, Moots RJ, Edwards SW: Neutrophil gene expression in rheumatoid arthritis. Pathophysiology (2005) 12(3):191-202.
80. Issekutz AC, Issekutz TB: Quantitation and kinetics of polymorphonuclear leukocyte and lymphocyte accumulation in joints during adjuvant arthritis in the rat. Lab Invest (1991) 64(5):656-663.
81. Wipke BT, Allen PM: Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol (2001) 167(3):1601-1608.
82. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD: Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol (2008) 9(4):415-423.
83. Nakasaki T, Tanaka T, Okudaira S, Hirosawa M, Umemoto E, Otani K, Jin S, Bai Z, Hayasaka H, Fukui Y, Aozasa K et al: Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. Am J Pathol (2008) 173(5):1566-1576.
84. Olsen NJ, Stein CM: New drugs for rheumatoid arthritis. N Engl J Med (2004) 350(21):2167-2179.
85. Osawa Y, Banno Y, Nagaki M, Brenner DA, Naiki T, Nozawa Y, Nakashima S, Moriwaki H: TNF-α-induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytes. J Immunol (2001) 167(1):173-180.
86. Niwa M, Kozawa O, Matsuno H, Kanamori Y, Hara A, Uematsu T: Tumor necrosis factor-α-mediated signal transduction in human neutrophils: Involvement of sphingomyelin metabolites in the priming effect of TNF-α on the fMLP-stimulated superoxide production. Life Sci (2000) 66(3):245-256.
87. Durgam GG, Virag T, Walker MD, Tsukahara R, Yasuda S, Liliom K, van Meeteren LA, Moolenaar WH, Wilke N, Siess W, Tigyi G et al: Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARγ, and inhibitors of autotaxin. J Med Chem (2005) 48(15):4919-4930.
88. 3 receptor antagonist. Bioorg Med Chem Lett (2004) 14(11):2735-2740.
89. 3 receptor antagonist. Mol Pharmacol (2001) 60(6):1173-1180.
90. Jiang G, Xu Y, Fujiwara Y, Tsukahara T, Tsukahara R, Gajewiak J, Tigyi G, Prestwich GD: α-Substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem (2007) 2(5):679-690.
91. Xu Y, Qian L, Prestwich GD: Synthesis of α-fuorinated phosphonates from α-fuorovinylphosphonates: A new route to analogues of lysophosphatidic acid. Org Lett (2003) 5(13):2267-2270.
92. Santos WL, Heasley BH, Jarosz R, Carter KM, Lynch KR, Macdonald TL: Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett (2004) 14(13):3473-3476.
93. Xu Y, Aoki J, Shimizu K, Umezu-Goto M, Hama K, Takanezawa Y, Yu S, Mills GB, Arai H, Qian L, Prestwich DD: Structure-activity relationships of fuorinated lysophosphatidic acid analogues. J Med Chem (2005) 48(9):3319-3327.
94. Fischer DJ, Nusser N, Virag T, Yokoyama K, Wang Da, Baker DL, Bautista D, Parrill AL, Tigyi G: Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol (2001) 60(4):776-784.
95. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J, Kimura T, Tobo M, Yamazaki Y, Watanabe T, Yagi M et al: Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol (2003) 64(4):994-1005.
96. Davis MD, Clemens JJ, Macdonald TL, Lynch KR: Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem (2005) 280(11):9833-9841.
97. Koide Y, Hasegawa T, Takahashi A, Endo A, Mochizuki N, Nakagawa M, Nishida A: Development of novel EDG3 antagonists using a 3D database search and their structure-activity relationships. J Med Chem (2002) 45(21):4629-4638.
98. Osada M, Yatomi Y, Ohmori T, Ikeda H, Ozaki Y: Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem Biophys Res Commun (2002) 299(3):483-487.
99. Peyruchaud O: Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer. Anticancer Agents Med Chem (2009) 9(4):381-391.
100. Pamuklar Z, Federico L, Liu S, Umezu-Goto M, Dong A, Panchatcharam M, Fulerson Z, Berdyshev E, Natarajan V, Fang X, Van Meerteren LA et al: Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem (2009) 284(11):7385-7394.
101. van Meeteren LA, Ruurs P, Christodoulou E, Goding JW, Takakusa H, Kikuchi K, Perrakis A, Nagano T, Moolenaar WH: Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem (2005) 280(22):21155-21161. •• Demonstrated that ATX is feedback inhibited by LPA, indicating that LPA can regulate its own synthesis. S1P was revealed as a potent physiological inhibitor of ATX.
102. Cui P, Tomsig JL, McCalmont WF, Lee S, Becker CJ, Lynch KR, Macdonald TL: Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors. Bioorg Med Chem Lett (2007) 17(6):1634-1640.
103. Ferry G, Moulharat N, Pradere JP, Desos P, Try A, Genton A, Giganti A, Beucher-Gaudin M, Lonchampt M, Bertrand M, Saulnier-Blache JS et al: S32826, a nanomolar inhibitor of autotaxin: Discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther (2008) 327(3):809-819.
104. Cui P, McCalmont WF, Tomsig JL, Lynch KR, Macdonald TL: α-and β-substituted phosphonate analogs of LPA as autotaxin inhibitors. Bioorg Med Chem (2008) 16(5):2212-2225.
105. Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, Murofushi H, Uchiyama A, Murakami-Murofushi K, Koh E, Bandle RW, Byun HS et al: Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem (2006) 281(32):22786-22793. •• Describes carba analogs of ccPA that are selective inhibitors of ATX and that were evaluated as anticancer drug therapy. Cancer cell invasion in vitro and melanoma cell metastasis in vivo were demonstrated to be inhibited by ccPA; the ATX-LPA axis was suggested to be an attractive target for anticancer and anti-angiogenesis therapy.
106. Xu Y, Jiang G, Tsukahara R, Fujiwara Y, Tigyi G, Prestwich GD: Phosphonothioate and fuoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors. J Med Chem (2006) 49(17):5309-5315.
107. Van Meeteren LA, Brinkmann V, Saulnier-Blache JS, Lynch KR, Moolenaar WH: Anticancer activity of FTY720: Phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Lett (2008) 266(2):203-208. • Describes the inhibition of the ATX-LPA axis as an additional target of FTY-720-P, and demonstrated that the anti-inflammatory effect of FTY-720 in animal models of arthritis may relate to FTY-720-P inhibiting the ATX-LPA axis, in addition to sequestering lymphocytes in secondary lymphoid organs.
108. Prestwich GD, Gajewiak J, Zhang H, Xu X, Yang G, Serban M: Phosphatase-resistant analogues of lysophosphatidic acid: Agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta (2008) 1781(9):588-594.
109. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, Fells JI, Perygin D, Parrill AL, Tigyi G, Prestwich GD: Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res (2009) 69(13):5441-5449.
110. Kihara A, Igarashi Y: Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochim Biophys Acta (2008) 1781(9):496-502.
111. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA et al: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem (2002) 277(24):21453-21457.
112. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, Lin CY, Hla T: Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem (2007) 282(12):9082-9089.
113. Schwab SR, Cyster JG: Finding a way out: Lymphocyte egress from lymphoid organs. Nat Immunol (2007) 8(12):1295-1301.
114. Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M, Ishihara T, Nonomura N et al: Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res (2002) 62(5):1410-1419.
115. Chua CW, Lee DT, Ling MT, Zhou C, Man K, Ho J, Chan FL, Wang X, Wong YC: FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer (2005) 117(6):1039-1048.
116. Matsuura M, Imayoshi T, Chiba K, Okumoto T: Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res (2000) 49(8):404-410.
117. Wang F, Tan W, Guo D, He S: Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720. Eur J Pharmacol (2007) 573 (1-3) : 230-240.
118. Mansoor M, Melendez AJ: Recent trials for FTY720 (fngolimod) : A new generation of immunomodulators structurally similar to sphingosine. Rev Recent Clin Trials (2008) 3(1):62-69.
119. Parrill AL, Echols U, Nguyen T, Pham TC, Hoeglund A, Baker DL: Virtual screening approaches for the identification of non-lipid autotaxin inhibitors. Bioorg Med Chem (2008) 16(4):1784-1795.
120. Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, Braddock DT: Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther (2008) 7(10):3352-3362.
121. Yamamoto T, Fujita K, Asari S, Chiba A, Kataba Y, Ohsumi K, Ohmuta N, Iida Y, Ijichi C, Iwayama S, Fukuchi N et al: Synthesis and evaluation of isoxazole derivatives as lysophosphatidic acid (LPA) antagonists. Bioorg Med Chem Lett (2007) 17(13):3736-3740.
122. 3 receptor. J Biol Chem (2003) 278(14):11962-11969. (Pubitemid 36800170)
123. Virag T, Elrod DB, Liliom K, Sardar VM, Parrill AL, Yokoyama K, Durgam G, Deng W, Miller DD, Tigyi G: Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol (2003) 63(5):1032-1042.
124. Wetter JA, Revankar C, Hanson BJ: Utilization of the Tango β-arrestin recruitment technology for cell-based EDG receptor assay development and interrogation. J Biomol Screen (2009) 14(9):1134-1141.
125. Jo E, Sanna MG, Gonzalez-Cabrera PJ, Thangada S, Tigyi G, Osborne DA, Hla T, Parrill AL, Rosen H: S1P1-selective in vivo-active agonists from high-throughput screening: Off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol (2005) 12(6):703-715.